INDOCO vs LUPIN: Stock Comparison

Indoco Remedies Limited vs Lupin Limited

Live data: 22 July 2026, 2:52 PM IST • Source: NSE and company filings

Lupin Limited is the larger company by market capitalisation. Indoco Remedies Limited shows a lower P/E, while Lupin Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Indoco Remedies Limited and Lupin Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, INDOCO is more favourable on 2 of 13 scored metrics and LUPIN on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
LUPIN is the larger company
₹1.1 L Cr vs ₹2,160 Cr
P/E Ratio
INDOCO has a lower P/E
-23.83x vs 21.56x
P/B Ratio
INDOCO has a lower P/B
2.41x vs 5.12x
EPS
LUPIN has higher earnings per share
₹116.56 vs ₹-10.71
Dividend Yield
LUPIN has a higher dividend yield
0.48% vs 0.08%
Revenue Growth (TTM YoY)
LUPIN has faster revenue growth
31.9% vs 21.9%
EPS Growth (TTM YoY)
LUPIN has faster EPS growth
89% vs 0%
Qtr Sales Growth
LUPIN has stronger quarterly sales growth
31.9% vs 21.9%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDOCOLUPIN
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINDOCOLUPIN
Live Price₹233.99₹2,408.7
Day Change-4.82%-4.22%
Volume71,68810.11 L
52-Week High₹336₹2,529.5
52-Week Low₹162.19₹1,836.8
Distance from 52W High-30.36%-4.78%

Valuation

MetricINDOCOLUPIN
Market Cap₹2,160 Cr₹1.1 L Cr
P/E Ratio-23.83x21.56x
P/B Ratio2.41x5.12x
EPS₹-10.71₹116.56
Book Value₹111.55₹491.29
Dividend Yield0.08%0.48%

Growth

MetricINDOCOLUPIN
Revenue Growth (TTM YoY)21.9%31.9%
EPS Growth (TTM YoY)0%89%
Qtr Sales Growth21.9%31.9%
Qtr Profit Growth39%101%

Profitability & Leverage

MetricINDOCOLUPIN
ROE-9.42%29.1%
ROCE0.93%30.3%
Net Margin-5.31%17.65%
Operating Margin7.68%31.5%
Debt to Equity1.16x0.29x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINDOCOLUPIN
Promoter Holding58.86%46.57% 0.04 pp
FII Holding1.27% 0.33 pp21.71% 0.22 pp
DII Holding17.68% 0.47 pp25.32% 0.26 pp
Public Holding22.04% 0.14 pp6.11% 0.08 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Indoco Remedies Limited and Lupin Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.